<DOC>
	<DOCNO>NCT02071225</DOCNO>
	<brief_summary>This phase II trial design evaluate efficacy obinutuzumab bendamustine treatment participant refractory relapse chronic lymphocytic leukemia ( CLL ) . Participants receive six 28-day cycle treatment . Treatment consist intravenous ( IV ) administration obinutuzumab bendamustine . Treatment time expect last 6 month , participant follow-up last 2 year .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Obinutuzumab Bendamustine Treatment Participants With Refractory Relapsed Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Age 18 year old Diagnosed CD20+ B chronic lymphocytic leukemia ( CLL ) accord National Cancer Institute ( NCI ) criteria Active disease meeting least 1 International Workshop CLL ( IWCLL ) 2008 criterion treatment Refractory CLL ( i.e . treatment failure progression treatment within 6 month last treatment ) relapse CLL ( i.e . participant meet criterion CR PR , progress beyond 6 month posttreatment ) At least 1 prior purine analogue bendamustine contain therapy Life expectancy great ( &gt; ) 6 month Use effective contraception describe study protocol Prior Alogenic Bone Marrow Transplant Greater equal ( &gt; /= ) 3 previous line chemotherapy and/or immunotherapy CLL Previous obinutuzumabcontaining regimen Treatment failure progression within 6 month bendamustinecontaining regimen Transformation CLL aggressive nonHodgkin lymphoma ( NHL ; Richter 's transformation ) Patients prolymphocytic transformation entry study either Active haemolytic anaemia Inadequate liver function History malignancy could affect compliance protocol interpretation result . Patients history malignancy treat curative intent exclude , unless malignancy remission without treatment &gt; /= 2 year prior enrolment . Patients history adequately treat carcinoma situ cervix ; basal squamous cell skin cancer ; low grade , early stage localize prostate cancer treat surgically curative intent ; good prognosis ductal carcinoma situ ( DCIS ) breast treated lumpectomy alone curative intent eligible Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include significant cardiovascular disease pulmonary disease Recent major surgery ( within 4 week prior start Cycle 1 ) , diagnosis Regular treatment corticosteroid 4 week prior study start , unless administer another condition dose equivalent less trhan equal ( &lt; /= ) 30 milligram per day ( mg/day ) prednisone Known active infection infection require treatment IV antibiotic hospitalization within 4 week prior study start Patients HIV , human T cell leukemia virus 1 ( HTLV1 ) , hepatitis B hepatitis C Pregnancy breastfeed Vaccination live vaccine within 4 week prior baseline visit Receipt study drug within 4 week prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>